Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):402–406. doi: 10.1038/bjc.1993.74

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

S C Fraser 1, H J Dobbs 1, S R Ebbs 1, L J Fallowfield 1, T Bates 1, M Baum 1
PMCID: PMC1968186  PMID: 8431375

Abstract

Forty patients with advanced breast cancer, randomised to receive CMF or weekly low dose Epirubicin, were evaluated by UICC criteria of response and WHO toxicity criteria, in addition to three QoL instruments: the 'Qualitator' daily diary card, 4 weekly Nottingham Health Profile (NHP) and Linear Analogue Self-Assessment (LASA). Response rates were 58% for CMF and 29% for epirubicin (chi 2 = 3.51, 1 d.f., P > 0.05). Median time to treatment failure was 24 weeks for CMF, 7 weeks for epirubicin (P < 0.05) but survival was similar in both groups. Survival was better for responders than for non-responders (medians 87 and 30 weeks, P = 0.02). CMF caused more objective alopecia (P < 0.001), nausea and vomiting (P < 0.001) and haematological toxicity (P < 0.02). However, QoL measures only recorded a significant difference in energy and pain, influenced primarily by the non-responders in each treatment group but with no difference in overall global scores. Scores for responders, irrespective of treatment, were better to start with (LASA P = 0.001); at 12 weeks, scores had improved (Qualitator P < 0.05; NHP P < 0.05). Scores in non-responders showed no change. In this small study aggressive chemotherapy gave better response and similar survival without impairing Quality of life overall. Detailed QoL measurement should be integral to all cancer chemotherapy trials.

Full text

PDF
402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A'Hern R. P., Ebbs S. R., Baum M. B. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer. 1988 Jun;57(6):615–618. doi: 10.1038/bjc.1988.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Addington-Hall J. M., MacDonald L. D., Anderson H. R. Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care? Br J Cancer. 1990 Oct;62(4):695–699. doi: 10.1038/bjc.1990.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baum M., Priestman T., West R. R., Jones E. M. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer. 1980;Suppl 1:223–226. [PubMed] [Google Scholar]
  4. Byrne M. Cancer chemotherapy and quality of life. BMJ. 1992 Jun 13;304(6841):1523–1524. doi: 10.1136/bmj.304.6841.1523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cassileth B. R., Lusk E. J., Guerry D., Blake A. D., Walsh W. P., Kascius L., Schultz D. J. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med. 1991 Apr 25;324(17):1180–1185. doi: 10.1056/NEJM199104253241706. [DOI] [PubMed] [Google Scholar]
  6. Chlebowski R. T., Smalley R. V., Weiner J. M., Irwin L. E., Bartolucci A. A., Bateman J. R. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group. Br J Cancer. 1989 Feb;59(2):227–230. doi: 10.1038/bjc.1989.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coates A., Gebski V., Bishop J. F., Jeal P. N., Woods R. L., Snyder R., Tattersall M. H., Byrne M., Harvey V., Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987 Dec 10;317(24):1490–1495. doi: 10.1056/NEJM198712103172402. [DOI] [PubMed] [Google Scholar]
  8. Ebbs S. R., Saunders J. A., Graham H., A'Hern R. P., Bates T., Baum M. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol. 1989;28(6):887–892. doi: 10.3109/02841868909092326. [DOI] [PubMed] [Google Scholar]
  9. Fraser S. C., Ebbs S. R., Dobbs H. J., Fallowfield L. J., Baum M. The design of advanced breast cancer trials. New approaches. Acta Oncol. 1990;29(3):397–400. doi: 10.3109/02841869009090021. [DOI] [PubMed] [Google Scholar]
  10. Harris A. L., Cantwell B. M., Carmichael J., Wilson R., Farndon J., Dawes P., Ghani S., Evans R. G. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990 Jan 27;335(8683):186–190. doi: 10.1016/0140-6736(90)90277-c. [DOI] [PubMed] [Google Scholar]
  11. Hunt S. M., McEwen J., McKenna S. P. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985 Apr;35(273):185–188. [PMC free article] [PubMed] [Google Scholar]
  12. Morris J. N., Sherwood S. Quality of life of cancer patients at different stages in the disease trajectory. J Chronic Dis. 1987;40(6):545–556. doi: 10.1016/0021-9681(87)90012-9. [DOI] [PubMed] [Google Scholar]
  13. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Powles T. J., Coombes R. C., Smith I. E., Jones J. M., Ford H. T., Gazet J. C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1980 Mar 15;1(8168 Pt 1):580–582. doi: 10.1016/s0140-6736(80)91066-1. [DOI] [PubMed] [Google Scholar]
  15. Priestman T. J., Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet. 1976 Apr 24;1(7965):899–900. doi: 10.1016/s0140-6736(76)92112-7. [DOI] [PubMed] [Google Scholar]
  16. Slevin M. L., Stubbs L., Plant H. J., Wilson P., Gregory W. M., Armes P. J., Downer S. M. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990 Jun 2;300(6737):1458–1460. doi: 10.1136/bmj.300.6737.1458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Spitzer W. O., Dobson A. J., Hall J., Chesterman E., Levi J., Shepherd R., Battista R. N., Catchlove B. R. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34(12):585–597. doi: 10.1016/0021-9681(81)90058-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES